Release date: December 9, 2024
Expiration date: December 9, 2025

Recent advances in molecular diagnostics and drug development have revolutionized how cancer is being diagnosed, risk stratified and treated. A host of new targeted therapies and immunotherapies have emerged, and many require companion diagnostic testing to identify which patients are most likely to respond to these therapies. This activity will cover recent advances in cancer diagnostics, with a focus on integrating precision medicine approaches. Topics will cover the latest molecular and genomic biomarkers used in cancer diagnostics, including their clinical implications for targeted therapies. Learners will gain insights into selecting and interpreting biomarker tests that drive individualized treatment decisions and improve patient outcomes.

Dahui Qin, MD, PhD
Medical Director of Molecular Diagnostic Laboratory, Moffitt Cancer Center
Senior Member, Hematopathology and Laboratory Medicine
Professor, Dept. of Oncologic Sciences, University of South Florida

This program is designed for pathologists.

At the conclusion of this activity, learners should be better able to:
• Define the role of precision medicine in enhancing the diagnostic accuracy and management of cancer.
• Identify key molecular and genomic biomarkers used in cancer diagnostics.
• Integrate precision medicine principles into routine pathology practice to guide targeted therapy decisions.

Support for this accredited continuing education activity has been made possible through educational grants from AstraZeneca and Daiichi Sankyo.

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and Florida Society of Pathologists (FSP). American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Healthcare Professionals
Other members of the care team will receive a certificate of participation.

Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the program evaluation.

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Faculty/Planner:
Dr. Qin has no relevant financial relationships with ineligible companies to disclose.

Planners:
John JD Juchniewicz, MCIS, CHCP, FACEHP - American Academy of CME: No relevant financial relationships with ineligible companies to disclose.
Erin Corrales - Florida Society of Pathologists: No relevant financial relationships with ineligible companies to disclose.
Joseph Kim, MD – Florida Society of Pathologists: No relevant financial relationships with ineligible companies to disclose.
Marilyn Bui, MD, PhD – Florida Society of Pathologists: Discloses the following relevant financial relationships:
Advisory Board/Consultant: Visiopharm, Aiforia, Roche, AstraZeneca, PathAI, DigitCells, Merck.

The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy or Florida Society of Pathologists. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information. This activity does not contain discussion of unlabeled/investigational usage.

For more information about the Florida Society of Pathologists privacy policy, please review: Privacy Notice

 

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm

For CME-related questions, contact CEServices@academycme.org

For all other questions, including technical issues, contact education@flpath.org